Daraxonrasib Achieves 60% Reduction in Mortality for Pancreatic Cancer Patients

In a groundbreaking Phase 3 trial, daraxonrasib significantly improves survival rates for patients with metastatic pancreatic ductal adenocarcinoma.

A
Aapla Nagpur Desk
20 Nov 2026, 7:22 PM IST · 2 min read
Source: Casrai
Daraxonrasib Achieves 60% Reduction in Mortality for Pancreatic Cancer Patients
KEY TAKEAWAYS
1

Daraxonrasib shows a median overall survival of 13.2 months, nearly double that of standard chemotherapy.

2

The trial confirms a 60% reduction in the risk of death for patients treated with daraxonrasib.

3

Safety profile indicates manageable side effects, primarily low-grade toxicities.

On November 18, 2026, researchers announced significant findings from the Phase 3 RASolute 302 trial, demonstrating that daraxonrasib, an oral multi-selective RAS(ON) inhibitor, nearly doubles overall survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Conducted globally, the trial compared daraxonrasib to standard chemotherapy, revealing a median overall survival of 13.2 months for the daraxonrasib group versus 6.7 months for the control group.

The RASolute 302 trial involved adult patients who had experienced cancer progression after one prior systemic treatment. The study, led by investigators at Dana-Farber Cancer Institute, achieved its primary and secondary endpoints with high statistical significance. Patients receiving daraxonrasib exhibited a 60% reduction in mortality risk, with a hazard ratio of 0.40. Additionally, the median progression-free survival was 7.2 months for daraxonrasib compared to 3.6 months for standard chemotherapy, indicating a substantial improvement in treatment efficacy.

In terms of response rates, daraxonrasib demonstrated a confirmed objective response rate of 30% to 32%, significantly higher than the 10% to 11% observed in the chemotherapy group. Furthermore, the treatment was associated with a delay in deterioration of quality of life and physical functioning, with manageable side effects primarily consisting of low-grade toxicities such as rash and diarrhea.

The implications of these findings are profound for the field of oncology, particularly for patients with limited treatment options. Pancreatic ductal adenocarcinoma, known for its poor prognosis and low survival rates, has historically posed significant challenges in treatment. The results from the RASolute 302 trial not only establish a new benchmark for therapeutic approaches but also pave the way for further research into targeted therapies for this aggressive cancer.

Looking ahead, regulatory bodies such as the FDA and EMA are reviewing daraxonrasib for approval in treating mPDAC. Additionally, ongoing studies, including the Phase 3 RASolute 303 trial, are set to explore the efficacy of daraxonrasib in combination with standard chemotherapy in first-line settings. Researchers will continue to monitor long-term survival rates and resistance mechanisms, ensuring that this promising treatment can be effectively integrated into clinical practice.

💬What did you think of this story?What did you think?

Read Next

Daraxonrasib Improves Survival in Pancreatic Cancer